Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor

Cancer Research

Volumn 60, Issue 10, 2000, Pages 2680-2688

  Omer, Charles A ^a,b   Chen, Zunxuan ^a,c   Diehl, Ronald E ^a   Conner, Michael W ^a,d   Chen, Howard Y ^a   Trumbauer, Myrna E ^a   Gopal Truter, Shobhna ^a   Seeburger, Gina ^a   Bhimnathwala, Hema ^a   Abrams, Marc T ^a   Davide, Joseph P ^a   Ellis, Michelle S ^a   Gibbs, Jackson B ^a   Greenberg, Ian ^a,e   Hamilton, Kelly ^a   Koblan, Kenneth S ^a   Kral, Astrid M ^a   Liu, Dongming ^a   Lobell, Robert B ^a   Miller, Patricia J ^a   Mosser, Scott D ^a   O'Neill, Timothy J ^a   Rands, Elaine ^a,c   Schaber, Michael D ^a   Senderak, Edith T ^a   Oliff, Allen ^a,f   Kohl, Nancy E ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Advanced Medicine Inc   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; COMPLEMENTARY DNA; ENZYME INHIBITOR; PROTEIN FARNESYLTRANSFERASE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSGENIC MOUSE; TUMOR XENOGRAFT; VIRUS CARCINOGENESIS;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; GENES, RAS; GROWTH INHIBITORS; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; METHIONINE; MICE; MICE, TRANSGENIC; PHENOTYPE; TRANSGENES;

EID: 0034658479     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Gibbs, J. B., Oliff, A., and Kohl, N. F., Farnesyltransferase inhibitors: Ras research yields a potenlial cancer therapeutic. Cell, 77: 175-178, 1994.
2. Barbacid, M. ras Genes. Annu. Rev. Biochem., 56: 779-827, 1987.
3. Bos, J. L. The ras gene family and human carcinogenesis. Mutat. Res., 195: 255-271, 1988.
4. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
5. Zhang, F. L., and Casey, P. J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem., 65: 241-269, 1996.
6. Willumsen, B. M., Morris, K., Papageorge, A. G., Hubbert, N. L., and Lowy, D. R. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J., 3: 2581-2585, 1984.
7. Hancock, J. F., Magec, A. I., Childs, J. E., and Marshall, C. J. All ras proteins are polyisoprenylated hut only some are palmitoylated. Cell, 57: 1167-1177, 1989.
8. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., and Der, C. J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA, 87: 3042-3046, 1990.
9. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 89: 6403-6407, 1992.
10. Zhang, F. L., Kirschmeier, P., Carr, D., James, L., Bond, R. W., Wang, L., Patton, R., Windsor, W. T., Syto, R., Zhang, R., and Bishop, W. R. Characterization of Ha-Ras. N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J. Biol. Chem., 272: 10232-10239, 1997.
11. Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., and Garcia, A. M. Direct demonstration of geranylgeranylalion and farnesylalion of Ki-Ras in vivo. J. Biol. Chem., 272: 14093-14097, 1997.
12. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishoip, W. R., and Pai, J-K. K-. and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
13. Cox, A. D., Hisaka, M. M., Buss, J. E., and Der, C. J. Specific isoprenoid modification is required for function of normal, but not oncogenic. Ras protein. Mol. Cell. Biol., 12: 2606-2615, 1992.
14. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., James, C., and Marsters, J. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC). 260: 1937-1942, 1993.
15. Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E. A., Graham, S. L., Gihbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol., 14: 4193-4202, 1994.
16. Manne, V., Van, N., Carboni, J. M., Tuomari, A. V., Ricca, C. S., Brown, J. G., Andahazy, M. L., Schmidt, R. J., Patel, D., Zahler, R., Weinmann, R., Der, C. J., Cox, A. D., Hunt, J. T., Gordon, E. M., Barbacid, M., and Seizinger, B. R. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene, 10: 1763-1779, 1995.
17. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
18. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 260: 1934-1937, 1993.
19. Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E. A., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T-J., Smith, R. L., Graham, S. L., Hartmen, G. D., Gibbs, J. B., and Oliff, A. Farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
20. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
21. Patel, D. V., Gordon, E. M., Schmidt, R. J., Weller, H. N., Young, M. G., Zahler, R., Barbacid, M., Carboni, J. M., Gullo-Brown, J. L., Hunihan, L., Ricca, C., Robinson, S., Seizinger, B. R., Tuomari, A. V., and Manne, V. Phosphinyl acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase. J. Med. Chem., 38: 435-442, 1995.
22. Hunt, J. T., Lee, V. G., Leftheris, K., Seizinger, B., Carboni, J., Mabus, J., Ricca, C., Yan, N., and Manne, V. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J. Med. Chem., 39: 353-358, 1996.
23. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M., Ferrari, E., Nielsen, L., Prioli, N., Dell, J., Sinha, D., Syed, J., Korfmacher, W. A., Nomeir, A. A., Lin, C-C., Wang, L., Taveras, A. G., Doll, R. J., Njoroge, F. G., Mallams, A. K., Remiszewski, S., Catino, J. J., Girijavallabhan, V. M., Kirschmeier, P., and Bishop, W. R. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice. Cancer Res., 58: 4947-4956, 1998.
24. Cox, A. D., Garcia, A. M., Westwick, J. K., Kowalczyk, J. J., Lewis, M. D., Brenner, D. A., and Der, C. J. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic Ras signaling and transformation. J. Biol. Chem., 269: 19203-19206, 1994.
25. Bishop, W. R., Bond, R., Petrin, J., Wang, L., Patton, R., Doll, R., Njoroge, G., Catino, J., Schwartz, J., Windsor, W., Syto, R., Schwartz, J., Carr, D., James, L., and Kirschmeier, P. Novel tricyclic inhibitors of farnesyl protein transferase. J Biol. Chem., 270: 30611-30618, 1995.
26. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FT1 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
27. Leftheris, K., Kline, T., Vite, G. D., Cho, Y. H., Bhide, R. S., Patel, D. V., Patel, M. M., Schmidt, R. J., Weller, H. N., Andahazy, M. L., Carboni, J. M., Gullo-Brown, J. L., Lee, F. Y. F., Ricca, C., Rose, W. C., Yan, N., Barbacid, M., Hunt, J. T., Meyers, C. A., Scizinger, B. R., Zahler, R., and Manne, V. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J. Med. Chem., 39: 224-236, 1996.
28. Njoroge, F. G., Vibulhhan, B., Rane, D. F., Bishop, W. R., Petrin, J., Patton, R., Bryant, M. S., Chen, K-J., Nomeir, A. A., Lin, C-C., Liu, M., King, I., Chen, J., Lee, S., Yaremko, B., Dell, J., Lipari, P., Malkowski, M., Li, Z., Catino, J., Doll, R. J., Girijavallabhan, V., and Ganguly, A. K. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4-18-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b] pyridin-11-ylidene)-piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds. J. Med. Chem., 40: 4290-4301. 1997.
29. Njoroge, F. G., Vibulbhan, B., Pinto, P., Bishop, W. R., Bryant, M. S., Nomeir, A. A., Lin, C.-C., Liu, M., Doll, R. J., Girijavallabhan, V., and Ganguly, A. K. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity. J. Med. Chem., 41: 1561-1567, 1998.
30. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Li, Z., Dell, J., Lipari, P., Malkowski, M., Prioli, N., Rossman, R. R., Korfmacher, W. A., Nomeir, A. A., Lin, C.-C., Mallams, A. K., Doll, R. J., catino, J. J., Girijavallabhan, V. M., Kirschmeier, P., and Bishop, W. R. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother. Pharmacol., 43: 50-58, 1999.
31. Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., and Leder, P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 49: 465-475, 1987.
32. Tremblay, P. J., Pothier, F., Hoang, T., Tremblay, G., Brownstein, S., Liszauer, A., and Jolicoeur, P. Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues. Mol. Cell. Biol., 9: 854-859, 1989.
33. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartmen, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
34. Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lu, S., Malumbres, M., Gibbs, J. B., Oliff, A., and Pellicer, A. Antitumor effect of a farnesyl transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res., 58: 1253-1259, 1998.
35. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
36. Yanisch-Perron, C., Vieira, J., and Messing, J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene, 33: 103-119, 1985.
37. Chan, H., Garon, C., Chang, E., Lowy, D., Hager, G. L., Scolnick, E. M., Repaske, R., and Martin, M. Molecular cloning of the Harvey sarcoma virus circular DNA intermediates. II further structural analysis. J. Virol., 33: 845-856, 1980.
38. Casey, P. J., Solski, P. A., Der, C. J., and Buss, J. E. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA. 86: 8323-8327, 1989.
39. Kozak, M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 44: 283-292, 1986.
40. Gordon, J. W., Scangos, G. A., Plotkin, D. J., Barbosa, J. A., and Ruddle, F. H. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl. Acad. Sci. USA, 77: 7380-7384, 1980.
41. Huang, A. L., Ostrowski, M. C., Berard, D., and Hager, G. L. Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus. Cell, 27: 245-255, 1981.
42. Stewart, T. A., Pattengale, P. K., and Leder, P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell, 38: 627-637, 1984.
43. Hogan, B., Beddington, R., Costantini, F., and Lacy, E. Manipulating the Mouse Embryo, Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1994.
44. Gibson, U. E. M., Held, C. A., and Williams, P. M. A novel method for real time quantitative RT-PCR. Genome Res., 6: 995-1001, 1996.
45. Dexter, D. L., Diamond, M., Creveling, J., and Chem, S-F. Chemotherapy of mammary carcinomas arising in ras transgenic mice. Invest. New Drugs, 11: 161-168, 1993.
46. Hollander, M., and Wolfe, D. A. Nonparametric Statistical Methods. New York: John Wiley and Sons, Inc., 1973.
47. Mangues, R., Seidman, I., Pellicer, A., and Gordon, J. W. Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene. Oncogene, 5: 491-497, 1990.
48. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
49. Chellaiah, A., Davis, A., and Mohanakumar, T. Cloning of a unique human homologue of the Escherichia coli DNAJ heat shock protein. Biochim. Biophys. Acta, 1174: 111-113, 1993.
50. Oh, S , Iwahori, A., and Kato, S. Human cDNA encoding DnaJ protein homologue. Biochim. Biophys. Acta, 1174: 114-116, 1993.
51. Davis, A. R., Alevy, Y. G., Chellaiah, A., Quinn, M. T., and Mohanakumar, T. Characterization of HDJ-2, a human 40 kDa heat shock protein. Int. J. Biochem. Cell Biol., 30: 1203-1221, 1998.
52. Kanazawa, M., Terada, K., Kato, S., and Mori, M. HSDJ, a human homolog of DnaJ, is farnesylated and is involved in protein import into mitochondria. J. Biochem., 121: 890-895, 1997.
53. Andres, A-C., Schonenberger, C-A., Groner, B., Hennighausen, L., LeMeur, M., and Gerlinger, P. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc. Natl. Acad. Sci. USA, 84: 1299-1303, 1987.
54. Quaife, C. J., Pinkert, C. A., Omitz, D. M., Palmiter, R. D., and Brinster, R. L. Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell, 48: 1023-1034, 1987.
55. Sandgren, E. P., Quaife, C. J., Pinkert, C. A., Palmiter, R. D., and Brinster, R. L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene, 4: 715-724, 1989.
56. Bailleul, B., Surani, M. A., White, S., Barton, S. C., Brown, K., Blessing, M., Jorcano, J., and Balmain, A. Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter. Cell, 62: 697-708, 1990.
57. Schaffner, D. L., Barrios, R., Massey, C., Banez, E. I., Ou, C-N., Rajagopalan, S., Aguilar-Cordova, E., Lebovitz, R. M., Overbeek, P. A., and Lieberman, M. W. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am. J. Pathol., 142: 1051-1060, 1993.
58. Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmnan, W., Kucherlapati, R., and Jacks, T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev., 11: 2468-2481, 1997.
59. Yan, J., Roy, S., Apolloni, A., Lane, A., and Hancock, J. F. Ras isoforms vary in their ability to activate raf-1 and phosphoinositide 3-kinase. J. Biol. Chem., 273: 24052-24056, 1998.
60. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (Washington DC), 260: 85-88, 1993.
61. Gibbs, J. B., and Oliff, A. The potential of farnesyltransferase inhibitors as cancer chcmotherapeutics. Annu. Rev. Pharmacol. Toxicol., 37: 143-166, 1997.